Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Legal Challenge To First Japan Rituxan Biosimilar Dismissed

Executive Summary

First Japan legal ruling means biosimilar competition can continue to gnaw away at Rituxan, at least for now, as Chugai faces rising challenges to its mature oncology portfolio.

You may also be interested in...



Approval Positions Roxadustat As Japan HIF-PHI Pioneer

The latest batch of product approvals in Japan positions Astellas’s roxadustat as the pioneer in the country’s potentially large HIF-PH inhibitor market in anemia, while Takeda and Meiji Seika see other important approvals and the first biosimilar teriparatide receives a nod.

Chugai Expects Limited Impact From First Biosimilar To Top Seller

First biosimilar version of Avastin approved in Japan, posing the first direct threat to Chugai's top product. But indications and timings mean the company expects limited impact this year.

Oncology, Orphans Dominate Japan Fiscal 2018 Approvals

Oncology again dominated new drug approvals in Japan last fiscal year, when expedited and special review pathways also played a major role in ensuring early access to new therapies.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL033172

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel